Avance Biosciences™ is excited to announce that we will be exhibiting at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4–8, 2026 at the Phoenix Convention Center in Phoenix, AZ. Visit us at Booth #528 during the Exhibit Hall to meet our team and discuss bioanalytical strategies supporting immuno-oncology development.
Key Topics Covered at SITC 2026
- Biomarkers, Immune Monitoring and Novel Technologies
- Cellular Therapies
- Checkpoint Blockade Therapy
- Combination Immunotherapies
- Immuno-Conjugates and Chimeric Molecules
- Immune Cell Types and Biology
- Novel Single-Agent Immunotherapies
Event Details
- Event: SITC 2026 (41st Annual Meeting & Pre-Conference Programs)
- Dates: November 4–8, 2026
- Location: Phoenix Convention Center, Phoenix, AZ
- Avance Booth: #528
Immunogenicity (ADA/NAb) Testing
Checkpoint inhibitors, bispecifics, and immune-conjugates all carry immunogenicity risk that must be characterized to support clinical development. Avance Biosciences provides tiered ADA screening, confirmatory, titer, and neutralizing antibody (NAb) assays aligned with current regulatory expectations.
Biomarker and Immune Monitoring Assays
Understanding how a therapy engages and modulates the immune system is central to immuno-oncology development. We offer biomarker discovery, cytokine profiling, and immune cell phenotyping by flow cytometry to support mechanism-of-action and response studies.
Cell and Gene Therapy Testing
Cellular therapies bring unique characterization and release-testing needs. Avance Biosciences supports potency, identity, and vector characterization assays for CAR-T and other cell-based immunotherapy programs, from early development through commercial release.
Bioanalytical Support for Combination Therapies
Combination immunotherapy regimens require bioanalytical strategies that can resolve multiple analytes and interactions. Our scientists design fit-for-purpose PK/PD and ligand-binding assays to support complex, multi-agent development programs.
Meet Avance Biosciences at Booth #528
SITC’s Annual Meeting brings together the leading researchers, clinicians, and industry scientists advancing the field of cancer immunotherapy. We look forward to meeting with attendees and discussing how Avance Biosciences can support your immuno-oncology development programs with regulatory-aligned bioanalytical testing.
Contact our technical team to discuss how we can support your immunogenicity, biomarker, and cell therapy testing needs.
We look forward to seeing you in Phoenix!
Accelerate your drug development with Avance Biosciences’ Next-Generation Sequencing (NGS) Center of Excellence, delivering GMP- and GLP-compliant genomics solutions to power your development programs. Our capabilities include Short-read Next-gen Sequencing, Nanopore Third-gen Sequencing, PacBio Third-gen Sequencing, 10X Chromium Single-cell Sequencing, and Mission Bio Tapestri Single-cell Sequencing. Learn more at our NGS Center of Excellence and contact our experts to get started.
